Production (Stage)
Avidity Biosciences, Inc.
RNA
$30.58
-$0.23-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -369.22M | -322.30M | -280.49M | -252.45M | -228.68M |
| Total Depreciation and Amortization | 2.92M | 2.78M | 2.65M | 2.51M | 2.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.44M | 33.21M | 32.83M | 32.36M | 30.54M |
| Change in Net Operating Assets | -27.46M | -14.56M | 60.50M | 61.91M | 55.31M |
| Cash from Operations | -355.32M | -300.87M | -184.50M | -155.67M | -140.48M |
| Capital Expenditure | -9.90M | -7.07M | -4.01M | -3.23M | -3.32M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -654.36M | -847.14M | -734.98M | -284.82M | 36.19M |
| Cash from Investing | -664.27M | -854.20M | -738.99M | -288.06M | 32.86M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 805.00M | 1.05B | 1.07B | 726.71M | 318.80M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -154.00K | 141.40M | 141.40M | 141.40M | 141.55M |
| Cash from Financing | 804.85M | 1.19B | 1.21B | 868.10M | 460.35M |
| Foreign Exchange rate Adjustments | 39.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -214.70M | 37.29M | 287.04M | 424.37M | 352.73M |